News Archive

This inaugural event will showcase technologies being developed at the National Cancer Institute (NCI) in Bethesda and Frederick, and Frederick National Laboratory for Cancer Research (FNLCR) to encourage startup formation, technology licensing, and collaborations. It will introduce the local scientific community to the regional technology development stakeholders and highlight available resources.

Prospective investors, established companies, interested stakeholders, and those looking to commercialize technologies are invited and encouraged to attend. The day will feature short technology summaries by NCI and FNLCR innovators, as well as presentations from regional stakeholders involved with technology development and commercialization. An interactive poster session by innovators and technology ambassadors will concurrently occur.

ABOUT THE USDD: Every six months, the University Startups Demo Day engages with universities to accept 200 of their best university startups to be scored by a Corporate Selection Committee consisting of Fortune 500 companies. These double-curated startups by academia and industry represent the very top startups coming out of American universities that are industry aligned. The University IP Into University Startups (IP2Startups) program provide Fortune 500 companies an effective way to identify university technologies that correspond to business unit needs that can be licensed or commercialized by university startups. Our Investor Roadshow program provides funding for select Demo Day companies that develop towards corporate milestones over 2-7 years from the IP2Start and Demo Day programs.

IP2Startups and USDD Corporate Selection Committee Pool Includes: Air Products – Specialized Chemicals | Astra Zeneca – Pharmaceuticals | Barilla – Food Processing | BASF – Diversified Chemicals | BMW – Auto & Truck Manufacturers | Dassault Systemes – Software & Programming | DuPont – Chemicals | Eastman Chemical Company – Specialized Chemicals | Eli Lilly and Co. – Pharmaceuticals | Evonik – Specialty chemicals | Faurecia – Automotive parts manufacturing | GlaxoSmithKline – Pharmaceuticals | Hyundai – Auto & Truck Manufacturers | IBM – Computer Services | Johnson & Johnson – Medical Equipment & Supplies | Janssen Pharmaceutical Companies of J&J – Pharmaceuticals | M Ventures (Merck KGaA) – Healthcare, Life Sciences, Performance Materials | Medline – Medical and Surgical Supplies | Pepsico – Beverages and Foods | Pfizer – Pharmaceuticals | SABIC – Chemicals | Saint-Gobain – Construction Materials | Sanofi – Pharmaceuticals | Schlumberger – Oil Services & Equipment | Sony – Consumer Electronics | The J.M. Smucker Company – Food Processing | Unilever – Household/Personal Care | Western Digital Capital – Computer Storage Devices

The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program.  The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying.

This is the third Challenge Project which the two organisations have run together.

UTC Cambridge students attended weekly sessions with scientists and business professionals from the MedImmune team to learn about many aspects of a medicine’s discovery and development, including scientific research, manufacturing and regulation. In addition to visiting MedImmune’s state-of-the-art laboratories at Granta Park, students also attended workshops, classes and practical sessions held at UTC Cambridge’s purpose-designed building at the Cambridge Biomedical Campus. In addition to gaining exposure to scientific research disciplines, students focused on practical and operational matters such as the importance of team work and collaboration, as well as wider concerns facing patients, government and industry on a global scale.

Pappas Capital, a life science venture capital firm, announced today that its new fund, Pappas Ventures V, recently invested in OrphoMed, a clinical stage company that is developing best-in-class therapies for treatment of inadequately-controlled gastrointestinal disorders. The investment in OrphoMed is the first investment by the new Pappas Ventures fund.

Event is for Post-Docs & Professional Scientists currently working in the Therapeutic Areas of:

• Oncology
• Respiratory, Inflammation & Autoimmunity •Cardiovascular & Metabolic Diseases •Infectious Diseases & Vaccines
• Related scientific disciplines

Event will include music, lawn games, hors d’oeuvres, drinks.

MedImmune fully supports and abides by the PhRMA Code on Interactions with Healthcare Professionals. MedImmune cannot accommodate or pay for the cost of a spouse or other guest of a healthcare professional. As such, this event is open to invitees only. If you are a prescriber and/or a Federal, State, or Institution employee, you may be subject to laws, regulations, or rules which prohibit, limit, or require the public disclosure of gifts, meals, or items of value you may receive. We ask that you comply with any such laws, regulations, or rules that govern your receipt of gifts, meals, or items of value. Please bring your State License Number (SLN) and National Provider Identifier (NPI) to the event. These will be used for reporting purposes where required by state and federal law (OPEN Payments). You may look up your NPI and SLN at http://www.npinumberlookup.org/.

TP Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on addressing oncology drug resistance, announced today that the company raised $45 million in a Series C financing round. The round was co-led by Lilly Asia Ventures (LAV), OrbiMed Advisors, LLC, and S.R. One, Limited, and joined by existing investors Cormorant Asset Management and SV Tech Ventures. In conjunction with the financing, Carl L. Gordon, Ph.D., CFA, General Partner at OrbiMed, Hongbo Lu, Ph.D., Partner at LAV, and Simeon J. George, M.D., Partner at S.R. One, joined the company’s Board of Directors.

Writing on trends, I frequently profile tech companies that use trends to outperform competitors. But using trends is not restricted to tech companies.

By following trends, since 1998 Alexandria Real Estate Equities has tripled the performance of the NASDAQ, quadrupled returns of the S&P 500, and quintupled the Russell 2000.  Alexandria has even outperformed technology stalwart Microsoft, and investment guru Berkshire Hathaway by 230%.